Sulforaphane alleviates hypoxic vestibular vertigo (HVV) by increasing NO production via upregulating the expression of NRF2

References

• Jonsson R, Sixt E, Landahl S, et al. Prevalence of dizziness and vertigo in an urban elderly population. J Vestib Res. 2004;14:47–52.
   PubMed Web of Science ®Google Scholar
• Neuhauser HK. Epidemiology of vertigo. Curr Opin Neurol. 2007;20:40–46.
   PubMed Web of Science ®Google Scholar
• Sloane PD, Coeytaux RR, Beck RS, et al. Dizziness: state of the science. Ann Intern Med. 2001;134:823–832.
   PubMed Web of Science ®Google Scholar
• Olesen J. Calcium entry blockers in the treatment of vertigo. Ann N Y Acad Sci. 1988;522:690–697.
   PubMed Web of Science ®Google Scholar
• Chen CP, Yeh CL, Yang YK, et al. The efficacy of sonic and ultrasonic appliances on root canal debridement. Zhonghua Ya Yi Xue Hui Za Zhi. 1990;9:51–60.
   PubMedGoogle Scholar
• Raponi G, Alpini D, Volonte S, et al. The role of free radicals and plasmatic antioxidant in Meniere’s syndrome. Int Tinnitus J. 2003;9:104–108.
   PubMedGoogle Scholar
• Goto F, Hayashi K, Kunihiro T, et al. The possible contribution of angiitis to the onset of benign paroxysmal positional vertigo (BPPV). Int Tinnitus J. 2010;16:25–28.
   PubMedGoogle Scholar
• Juge N, Mithen RF, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007;64:1105–1127.
   PubMed Web of Science ®Google Scholar
• Cuadrado A, Rojo AI, Wells G, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019;18:295–317.
   PubMed Web of Science ®Google Scholar
• Zhang DD, Hannink M. Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003;23:8137–8151.
   PubMed Web of Science ®Google Scholar
• Hu C, Eggler AL, Mesecar AD, et al. Modification of keap1 cysteine residues by sulforaphane. Chem Res Toxicol. 2011;24:515–521.
   PubMed Web of Science ®Google Scholar
• Ahn YH, Hwang Y, Liu H, et al. Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc Natl Acad Sci U S A. 2010;107:9590–9595.
   PubMed Web of Science ®Google Scholar
• Ekeloef S, Halladin N, Fonnes S, et al. Effect of intracoronary and intravenous melatonin on myocardial salvage index in patients with ST-elevation myocardial infarction: a randomized placebo controlled trial. J Cardiovasc Transl Res. 2017;10:470–479.
   PubMed Web of Science ®Google Scholar
• Penna C, Mancardi D, Rastaldo R, et al. Cardioprotection: a radical view free radicals in pre and postconditioning. Biochim Biophys Acta. 2009;1787:781–793.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002;99:11908–11913.
   PubMed Web of Science ®Google Scholar
• Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev. 2006;38:769–789.
   PubMed Web of Science ®Google Scholar
• Rada P, Rojo AI, Chowdhry S, et al. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol. 2011;31:1121–1133.
   PubMed Web of Science ®Google Scholar
• Chowdhry S, Zhang Y, McMahon M, et al. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene. 2013;32:3765–3781.
   PubMed Web of Science ®Google Scholar
• Wu T, Zhao F, Gao B, et al. Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 2014;28:708–722.
   PubMed Web of Science ®Google Scholar
• Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426. PMID: 23294312; PMCID: PMC4680839.
   PubMed Web of Science ®Google Scholar
• Erkens R, Suvorava T, Sutton TR, et al. Nrf2 deficiency unmasks the significance of nitric oxide synthase activity for cardioprotection. Oxid Med Cell Longev. 2018;2018:8309698.
   PubMed Web of Science ®Google Scholar
• Um HC, Jang JH, Kim DH, et al. Nitric oxide activates Nrf2 through S-nitrosylation of Keap1 in PC12 cells. Nitric Oxide. 2011;25(2):161–168.
   PubMed Web of Science ®Google Scholar
• Shehatou GS, Suddek GM. Sulforaphane attenuates the development of atherosclerosis and improves endothelial dysfunction in hypercholesterolemic rabbits. Exp Biol Med (Maywood). 2016;241:426–436.
   PubMed Web of Science ®Google Scholar
• Marklund SL. Superoxide dismutase isoenzymes in tissues and plasma from New Zealand black mice, nude mice and normal BALB/c mice. Mutat Res. 1985;148(1–2):129–134.
   PubMed Web of Science ®Google Scholar
• Granger DL, Taintor RR, Boockvar KS, et al. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol. 1996;268:142–151.
   PubMed Web of Science ®Google Scholar
• Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem. 1995;41(6 Pt 1):904–907.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Kostov RV. Glucosinolates and isothiocyanates in health and disease. Trends Mol Med. 2012;18:337–347.
   PubMed Web of Science ®Google Scholar
• Byrne MM, Murphy RT, Ryan AW. Epigenetic modulation in the treatment of atherosclerotic disease. Front Genet. 2014;5:364.
   PubMed Web of Science ®Google Scholar
• Tarozzi A, Angeloni C, Malaguti M, et al. Sulforaphane as a potential protective phytochemical against neurodegenerative diseases. Oxid Med Cell Longev. 2013;2013:415078.
   PubMed Web of Science ®Google Scholar
• Brandenburg LO, Kipp M, Lucius R, et al. Sulforaphane suppresses LPS-induced inflammation in primary rat microglia. Inflamm Res. 2010;59:443–450.
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Pollock JS, Nakane M, et al. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci U S A. 1991;88:365–369.
   PubMed Web of Science ®Google Scholar
• Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal. 2011;23:1921–1926.
   PubMed Web of Science ®Google Scholar
• Leoncini E, Malaguti M, Angeloni C, et al. Cruciferous vegetable phytochemical sulforaphane affects phase II enzyme expression and activity in rat cardiomyocytes through modulation of Akt signaling pathway. J Food Sci. 2011;76:H175–181.
   PubMed Web of Science ®Google Scholar
• Xin Y, Bai Y, Jiang X, et al. Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ss/Fyn pathway. Redox Biol. 2018;15:405–417.
   PubMed Web of Science ®Google Scholar
• Moi P, Chan K, Asunis I, et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A. 1994;91:9926–9930.
   PubMed Web of Science ®Google Scholar
• Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236:313–322.
   PubMed Web of Science ®Google Scholar
• Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem. 1991;266:11632–11639.
   PubMed Web of Science ®Google Scholar
• Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic Biol Med. 2004;36:1199–1207.
   PubMed Web of Science ®Google Scholar
• Gucluturk MT, Unal ZN, Ismi O, et al. The role of oxidative stress and inflammatory mediators in benign paroxysmal positional vertigo. J Int Adv Otol. 2016;12:101–105.
   PubMed Web of Science ®Google Scholar